ABBVIE
An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- Conditions
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 47
- Registration Number
- NCT06443775
- Locations
- 🇺🇸
Saint Louis Eye Institute /ID# 263275, Town And Country, Missouri, United States
An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 52
- Registration Number
- NCT06439394
- Locations
- 🇺🇸
Southern College of Optometry /ID# 262668, Memphis, Tennessee, United States
Expanded Access to ABBV-787
- Conditions
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06439966
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT06428019
- Locations
- 🇺🇸
Springfield Clinic /ID# 270145, Springfield, Illinois, United States
🇺🇸Oklahoma Cancer Specialists and Research Institute /ID# 267643, Tulsa, Oklahoma, United States
🇫🇷Centre Hospitalier de la Côte Basque /ID# 266847, Bayonne, Pyrenees-Atlantiques, France
An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China
- Conditions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1000
- Registration Number
- NCT06421740
- Locations
- 🇨🇳
The First Affiliated Hospital of Kunming Medical College /ID# 273451, Kunming, Yunnan, China
🇨🇳Beijing Anzhen Hospital /ID# 273443, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 264193, Beijing, Beijing, China
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.
- Conditions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 48
- Registration Number
- NCT06414798
- Locations
- 🇺🇸
Acpru /Id# 264249, Grayslake, Illinois, United States
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT06417775
- Locations
- 🇺🇸
New England Institute for Clinical Research /ID# 264019, Stamford, Connecticut, United States
🇺🇸Central Research Associates /ID# 260161, Birmingham, Alabama, United States
🇺🇸MD First Research - Chandler /ID# 262564, Chandler, Arizona, United States
A Study in Healthy Adult Participants to Assess the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of a Ravagalimab Subcutaneous Formulation in a Pre-Filled Syringe
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 12
- Registration Number
- NCT06402513
- Locations
- 🇺🇸
Acpru /Id# 265325, Grayslake, Illinois, United States
A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 207
- Registration Number
- NCT06399718
- Locations
- 🇺🇸
Westside Aesthetics /ID# 248232, Los Angeles, California, United States
🇺🇸Private Practice - Dr. Steven G. Yoelin /ID# 268046, Newport Beach, California, United States
🇺🇸Pacific Clinical Innovations /ID# 248231, Vista, California, United States
A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 112
- Registration Number
- NCT06390722